Scalper1 News
Generic and specialty drug giant Actavis (ACT) beat Wall Street’s Q3 estimates and raised its guidance early Wednesday, sending shares up more than 3% in early trading in the stock market today to a new high above 254. By midmorning, though, the stock was up just a fraction, near 246. Actavis’ earnings, excluding one-time items, rose 53% over the year-earlier quarter to $3.19 a share, beating analysts’ consensus by 9 cents, according to Thomson Scalper1 News
Scalper1 News